{
    "nct_id": "NCT03077659",
    "official_title": "Phase IIa Dose Escalation Trial of NanoPac® Focal Therapy for Prostate Cancer in Subjects Undergoing Radical Prostatectomy",
    "inclusion_criteria": "* Male; 18 years of age and older\n* Histopathologically proven adenocarcinoma, Gleason grade ≥ 7 of the prostate planned radical prostatectomy; appropriate for treatment with paclitaxel therapy\n* ECOG of 0 or 1\n* Laboratory requirements:\n\n  * WBC >2500/mm3\n  * Neutrophil >1500/mm3\n  * Hemoglobin >10 mg/dL\n  * Platelet >100,000/ mm3\n  * AST and ALT <2.5 x ULN\n  * Total bilirubin <1.5 x ULN\n  * Creatinine <2 mg/dL\n  * Normal PT/INR and PTT;\n* Willing to use appropriate contraception from time of NanoPac® injection until prostatectomy\n* Willing to receive an mpMRI\nHealthy volunteers allowed\nMust be MALE\nMust have minimum age of 18 Years",
    "exclusion_criteria": "* Evidence of locally advanced or metastatic disease;\n* Prostate size ≥ 50 cc\n* Prior prostatectomy\n* Anticipated use of concomitant chemotherapy (other than the protocol specified agents), immunotherapy, or systemic use of hormonal therapy (such as GnRH analogs, antiandrogens, androgen receptor inhibitors, and 5-α reductase inhibitors) prior to surgery\n* Treatment with a prior investigational agent within 30 days of first dose of investigational medication\n* Any previous local treatment of the prostate (i.e. radiation)\n* Any other condition (e.g. psychiatric disorder) that, in the opinion of the Investigator, may interfere with the patient's ability to comply with the study requirements or visit schedule\n* Known sensitivity to any of the study medication components\n* History of prior malignancy that has not been in remission for >5 years, with the exception of basal cell or squamous cell carcinoma.",
    "miscellaneous_criteria": ""
}